Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 164Active not recruiting 47Recruiting 45Unknown 35Terminated 27Withdrawn 5Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

zilucoplan 1rozanolixizumab 1fludarabine phosphate 1fludarabine 1exemestane 1epigallocatechin gallate 1durvalumab 1aumolertinib 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Vincristine 1Tamoxifen 1Sodium Chloride 1R-CHOP protocol 1Prednisone 1Pemetrexed 1Omeprazole 1Melphalan 1Loperamide 1Letrozole 1High-Energy Shock Waves 1Gastroscopy 1Etoposide 1Doxorubicin 1Dexamethasone 1Decitabine 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Catechin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Enrolling by invitation × Dexamethasone × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡